Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05853965 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma

Study acronym: BELI(E)VE
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 2026 to Apr 2027
    • Study completion date: Dec 2026 to Dec 2028
    v4
  2. Study sites: 1 to 5
    • Eligibility criteria shortened, about 55 words
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2023 to Jun 28, 2023
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn about the safety and efficacy of the drug combination belantamab mafodotin and venetoclax, with or without the addition of dexamethasone, in patients with relapsed/refractory multiple myeloma bearing the translocation t(11;14)
Trial Details
NCT Number NCT05853965
Lead Sponsor Universitätsklinikum Hamburg-Eppendorf
Conditions
(from sponsor)		 Multiple Myeloma, Multiple Myeloma in Relapse
Related terms Multiple Myeloma
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov